ZA200208186B - Synthetic process for the manufacture of an ecteinaschidin compound. - Google Patents
Synthetic process for the manufacture of an ecteinaschidin compound. Download PDFInfo
- Publication number
- ZA200208186B ZA200208186B ZA200208186A ZA200208186A ZA200208186B ZA 200208186 B ZA200208186 B ZA 200208186B ZA 200208186 A ZA200208186 A ZA 200208186A ZA 200208186 A ZA200208186 A ZA 200208186A ZA 200208186 B ZA200208186 B ZA 200208186B
- Authority
- ZA
- South Africa
- Prior art keywords
- process according
- group
- hydroxy
- protected
- formula
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 46
- 150000001875 compounds Chemical class 0.000 title claims description 41
- 238000004519 manufacturing process Methods 0.000 title claims description 5
- 229960000977 trabectedin Drugs 0.000 claims description 24
- PKVRCIRHQMSYJX-AIFWHQITSA-N trabectedin Chemical compound C([C@@]1(C(OC2)=O)NCCC3=C1C=C(C(=C3)O)OC)S[C@@H]1C3=C(OC(C)=O)C(C)=C4OCOC4=C3[C@H]2N2[C@@H](O)[C@H](CC=3C4=C(O)C(OC)=C(C)C=3)N(C)[C@H]4[C@@H]21 PKVRCIRHQMSYJX-AIFWHQITSA-N 0.000 claims description 23
- XXPXYPLPSDPERN-UHFFFAOYSA-N Ecteinascidin 743 Natural products COc1cc2C(NCCc2cc1O)C(=O)OCC3N4C(O)C5Cc6cc(C)c(OC)c(O)c6C(C4C(S)c7c(OC(=O)C)c(C)c8OCOc8c37)N5C XXPXYPLPSDPERN-UHFFFAOYSA-N 0.000 claims description 14
- 125000006239 protecting group Chemical group 0.000 claims description 10
- 230000015572 biosynthetic process Effects 0.000 claims description 8
- 230000032050 esterification Effects 0.000 claims description 7
- 238000005886 esterification reaction Methods 0.000 claims description 7
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 7
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- -1 methoxyethoxymethyl group Chemical group 0.000 claims description 5
- LJCZNYWLQZZIOS-UHFFFAOYSA-N 2,2,2-trichlorethoxycarbonyl chloride Chemical compound ClC(=O)OCC(Cl)(Cl)Cl LJCZNYWLQZZIOS-UHFFFAOYSA-N 0.000 claims description 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 2
- 125000001424 substituent group Chemical group 0.000 claims description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 claims 1
- BHINEHROXMLHMV-BVRLQDJESA-N C([C@H](N1C)[C@@H]2C#N)C3=CC(C)=C(OC)C(O)=C3[C@@H]1[C@H](C1)N2[C@@H](CNC(=O)[C@H](C)N)C2=C1C(=O)C(C)=C(OC)C2=O Chemical compound C([C@H](N1C)[C@@H]2C#N)C3=CC(C)=C(OC)C(O)=C3[C@@H]1[C@H](C1)N2[C@@H](CNC(=O)[C@H](C)N)C2=C1C(=O)C(C)=C(OC)C2=O BHINEHROXMLHMV-BVRLQDJESA-N 0.000 claims 1
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 claims 1
- 125000004423 acyloxy group Chemical group 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 229940126543 compound 14 Drugs 0.000 claims 1
- 125000000468 ketone group Chemical group 0.000 claims 1
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 claims 1
- 230000000269 nucleophilic effect Effects 0.000 claims 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 229930190585 Saframycin Natural products 0.000 description 25
- 239000000543 intermediate Substances 0.000 description 15
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 13
- 238000006243 chemical reaction Methods 0.000 description 8
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 7
- 241000243142 Porifera Species 0.000 description 6
- 229930188681 renieramycin Natural products 0.000 description 6
- JNEGMBHBUAJRSX-SHUHUVMISA-N saframycin a Chemical compound C([C@H](N1C)[C@@H]2C#N)C(C(C(C)=C(OC)C3=O)=O)=C3[C@@H]1[C@H](C1)N2[C@@H](CNC(=O)C(C)=O)C2=C1C(=O)C(C)=C(OC)C2=O JNEGMBHBUAJRSX-SHUHUVMISA-N 0.000 description 6
- 239000003242 anti bacterial agent Substances 0.000 description 5
- 230000000259 anti-tumor effect Effects 0.000 description 5
- 229940088710 antibiotic agent Drugs 0.000 description 5
- 238000010511 deprotection reaction Methods 0.000 description 5
- 241000187389 Streptomyces lavendulae Species 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 238000006722 reduction reaction Methods 0.000 description 4
- 125000002653 sulfanylmethyl group Chemical group [H]SC([H])([H])[*] 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 229930183496 Safracin Natural products 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 229930014626 natural product Natural products 0.000 description 3
- 150000003138 primary alcohols Chemical class 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 230000009466 transformation Effects 0.000 description 3
- 238000000844 transformation Methods 0.000 description 3
- UWYZHKAOTLEWKK-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinoline Chemical compound C1=CC=C2CNCCC2=C1 UWYZHKAOTLEWKK-UHFFFAOYSA-N 0.000 description 2
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 2
- WIDDOXWCZPPHAX-UHFFFAOYSA-N 4a,5,6,7-tetrahydro-4h-isoquinoline-1,3-dione Chemical compound C1CCC=C2C(=O)NC(=O)CC21 WIDDOXWCZPPHAX-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- LMKHFHFSEWJQID-UHFFFAOYSA-N Saframycin B Natural products COC1=C(C)C(=O)C2=C(CC3C4N(C)C(CN3C2CNC(=O)C(=O)C)CC5=C4C(=O)C(=C(C)C5=O)OC)C1=O LMKHFHFSEWJQID-UHFFFAOYSA-N 0.000 description 2
- 241000251555 Tunicata Species 0.000 description 2
- ZGVLLWBYFNMAOM-UHFFFAOYSA-N ac1l51xm Chemical compound C1C(N2C)CC(C(C(C)=C(OC)C3=O)=O)=C3C2C(C2)N1C(CNC(=O)C(C)O)C1=C2C(=O)C(C)=C(OC)C1=O ZGVLLWBYFNMAOM-UHFFFAOYSA-N 0.000 description 2
- 229930013930 alkaloid Natural products 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 125000000687 hydroquinonyl group Chemical group C1(O)=C(C=C(O)C=C1)* 0.000 description 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- KOHPLTGVBZMVDW-BBTHKVSRSA-N saframycin b Chemical compound C([C@@H](N1C)C2)C(C(C(C)=C(OC)C3=O)=O)=C3[C@H]1[C@H](C1)N2[C@@H](CNC(=O)C(C)=O)C2=C1C(=O)C(C)=C(OC)C2=O KOHPLTGVBZMVDW-BBTHKVSRSA-N 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 125000000037 tert-butyldiphenylsilyl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1[Si]([H])([*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- QSLZNGPMBOCIAZ-QSNGQZDXSA-N 113036-78-5 Chemical compound C12=C(O)C(OC)=C(C)C(O)=C2[C@H](OC)[C@H]2N(C)[C@@H]1[C@H](CC=1C(C(C)=C(OC)C(=O)C=1[C@@H]1CNC(=O)[C@H](C)N)=O)N1[C@H]2O QSLZNGPMBOCIAZ-QSNGQZDXSA-N 0.000 description 1
- QGNQEODJYRGEJX-UHFFFAOYSA-N 4h-isoquinoline-1,3-dione Chemical class C1=CC=C2C(=O)NC(=O)CC2=C1 QGNQEODJYRGEJX-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-OUBTZVSYSA-N Carbon-13 Chemical compound [13C] OKTJSMMVPCPJKN-OUBTZVSYSA-N 0.000 description 1
- 241000798368 Ecteinascidia Species 0.000 description 1
- 241000798369 Ecteinascidia turbinata Species 0.000 description 1
- YMAUZYADYYYPHZ-UHFFFAOYSA-N Ecteinascidin 770 Natural products COc1cc2C(NCCc2cc1O)C(=O)OCC3N4C(C#N)C5Cc6cc(C)c(OC)c(O)c6C(C4C(S)c7c(OC(=O)C)c(C)c8OCOc8c37)N5C YMAUZYADYYYPHZ-UHFFFAOYSA-N 0.000 description 1
- 241000186359 Mycobacterium Species 0.000 description 1
- 241000863422 Myxococcus xanthus Species 0.000 description 1
- CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000187654 Nocardia Species 0.000 description 1
- 235000010582 Pisum sativum Nutrition 0.000 description 1
- 240000004713 Pisum sativum Species 0.000 description 1
- 241000589540 Pseudomonas fluorescens Species 0.000 description 1
- HBULEGBKIIJRCH-UHFFFAOYSA-N Renieramycin B Natural products O=C1C(C)=C(OC)C(=O)C2=C1C(OCC)C1CN3C(COC(=O)C(C)=CC)C(C(=O)C(OC)=C(C)C4=O)=C4CC3C2N1C HBULEGBKIIJRCH-UHFFFAOYSA-N 0.000 description 1
- HHQBCXAQIYVYGF-UHFFFAOYSA-N Renieramycin D Natural products O=C1C(C)=C(OC)C(=O)C2=C1C(OCC)C1C(=O)N3C(COC(=O)C(C)=CC)C(C(=O)C(OC)=C(C)C4=O)=C4CC3C2N1C HHQBCXAQIYVYGF-UHFFFAOYSA-N 0.000 description 1
- BGHIUZDGPHSOIT-UHFFFAOYSA-N Renieramycin E Natural products OC1C(N2C)CC(C(C(C)=C(OC)C3=O)=O)=C3C2C(C2)N1C(COC(=O)C(C)=CC)C1=C2C(=O)C(C)=C(OC)C1=O BGHIUZDGPHSOIT-UHFFFAOYSA-N 0.000 description 1
- MAZLTHBYATZOCX-UHFFFAOYSA-N Renierone Natural products COC1=C(C)C(=O)c2ccnc(OC(=O)C(=C/C)C)c2C1=O MAZLTHBYATZOCX-UHFFFAOYSA-N 0.000 description 1
- 241000316848 Rhodococcus <scale insect> Species 0.000 description 1
- AZDDAJXLYMVMAW-FKTFMUQYSA-N Safracin A Natural products O=C(NC[C@@H]1N2[C@H]([C@@H]3N(C)[C@H](C2)Cc2c3c(O)c(OC)c(C)c2)CC=2C(=O)C(C)=C(OC)C(=O)C1=2)[C@@H](N)C AZDDAJXLYMVMAW-FKTFMUQYSA-N 0.000 description 1
- GKUZBRIJGIGFKC-UHFFFAOYSA-N Safracin B Natural products OC1C(N2C)CC3=CC(C)=C(OC)C(O)=C3C2C(C2)N1C(CNC(=O)C(C)N)C1=C2C(=O)C(C)=C(OC)C1=O GKUZBRIJGIGFKC-UHFFFAOYSA-N 0.000 description 1
- WVBLIKAXDJHLIE-UHFFFAOYSA-N Saframycin C Natural products COC1C2CN3C(CC4=C(C3CNC(=O)C(=O)C)C(=O)C(=C(OC)C4=O)C)C(N2C)C5=C1C(=O)C(=C(OC)C5=O)C WVBLIKAXDJHLIE-UHFFFAOYSA-N 0.000 description 1
- YQQUMADRNAOVHP-UHFFFAOYSA-N Saframycin G Natural products CN1C(C2C#N)C(O)C(C(C(C)=C(OC)C3=O)=O)=C3C1C(C1)N2C(CNC(=O)C(C)=O)C2=C1C(=O)C(C)=C(OC)C2=O YQQUMADRNAOVHP-UHFFFAOYSA-N 0.000 description 1
- QSLZNGPMBOCIAZ-UHFFFAOYSA-N Saframycin Mx 1 Natural products C12=C(O)C(OC)=C(C)C(O)=C2C(OC)C2N(C)C1C(CC=1C(C(C)=C(OC)C(=O)C=1C1CNC(=O)C(C)N)=O)N1C2O QSLZNGPMBOCIAZ-UHFFFAOYSA-N 0.000 description 1
- UFWYPWFCNWILJC-UHFFFAOYSA-N Saframycin Mx 2 Natural products COC1C2CN3C(CC4=C(C3CNC(=O)C(C)N)C(=O)C(=C(C)C4=O)OC)C(N2C)c5c(O)c(OC)c(C)c(O)c15 UFWYPWFCNWILJC-UHFFFAOYSA-N 0.000 description 1
- KLKJKXQSKPPFSJ-UHFFFAOYSA-N Saframycin Y3 Natural products CN1C(C2C#N)CC(C(C(C)=C(OC)C3=O)=O)=C3C1C(C1)N2C(CNC(=O)C(C)N)C2=C1C(=O)C(C)=C(OC)C2=O KLKJKXQSKPPFSJ-UHFFFAOYSA-N 0.000 description 1
- DULAUWVTCHNVOZ-UHFFFAOYSA-N Saframycin YD-2 Natural products CN1C(C2C#N)CC(C(C(C)=C(OC)C3=O)=O)=C3C1C(C1)N2C(CNC(=O)CN)C2=C1C(=O)C(C)=C(OC)C2=O DULAUWVTCHNVOZ-UHFFFAOYSA-N 0.000 description 1
- 101710137710 Thioesterase 1/protease 1/lysophospholipase L1 Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 241000778209 Xestospongia Species 0.000 description 1
- KFMCPROYQLHBSO-UHFFFAOYSA-N [C].C1NCCC2=CC=CC=C12 Chemical compound [C].C1NCCC2=CC=CC=C12 KFMCPROYQLHBSO-UHFFFAOYSA-N 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- GKUZBRIJGIGFKC-XPXFATIHSA-N antibiotic em 5519 Chemical compound C([C@@H](N1C)[C@@H]2O)C3=CC(C)=C(OC)C(O)=C3[C@H]1[C@H](C1)N2[C@@H](CNC(=O)[C@H](C)N)C2=C1C(=O)C(C)=C(OC)C2=O GKUZBRIJGIGFKC-XPXFATIHSA-N 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000003851 biochemical process Effects 0.000 description 1
- 235000010633 broth Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 150000001944 cysteine derivatives Chemical class 0.000 description 1
- FKBKETJRCKZDAM-SDBDLDFRSA-N decyano-saframycin a Chemical compound C([C@@H](N1C)[C@@H]2O)C(C(C(C)=C(OC)C3=O)=O)=C3[C@H]1[C@H](C1)N2[C@@H](CNC(=O)C(C)=O)C2=C1C(=O)C(C)=C(OC)C2=O FKBKETJRCKZDAM-SDBDLDFRSA-N 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
- BGFXHQYUWCGGLL-QWIBJBKUSA-N ecteinascidin 770 Chemical compound C([C@@]1(C(OC2)=O)NCCC3=C1C=C(C(=C3)O)OC)S[C@@H]1C3=C(OC(C)=O)C(C)=C4OCOC4=C3[C@H]2N2[C@@H](C#N)[C@H](CC=3C4=C(O)C(OC)=C(C)C=3)N(C)[C@H]4[C@@H]21 BGFXHQYUWCGGLL-QWIBJBKUSA-N 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 150000002440 hydroxy compounds Chemical class 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000002183 isoquinolinyl group Chemical class C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 150000003951 lactams Chemical class 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 231100001224 moderate toxicity Toxicity 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- VHXCHPIQWWKYPI-UHFFFAOYSA-N renieramycin C Natural products CN1C(C2=O)C(O)C(C(C(C)=C(OC)C3=O)=O)=C3C1C(C1)N2C(COC(=O)C(C)=CC)C2=C1C(=O)C(C)=C(OC)C2=O VHXCHPIQWWKYPI-UHFFFAOYSA-N 0.000 description 1
- JGSPEFLRDJUZIE-WEVVVXLNSA-N renierone Chemical compound C1=NC(COC(=O)C(\C)=C\C)=C2C(=O)C(OC)=C(C)C(=O)C2=C1 JGSPEFLRDJUZIE-WEVVVXLNSA-N 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- AZDDAJXLYMVMAW-BVFBRMCBSA-N safracin a Chemical compound C([C@@H](N1C)C2)C3=CC(C)=C(OC)C(O)=C3[C@H]1[C@H](C1)N2[C@@H](CNC(=O)[C@H](C)N)C2=C1C(=O)C(C)=C(OC)C2=O AZDDAJXLYMVMAW-BVFBRMCBSA-N 0.000 description 1
- JIJFDUYXCLTCFT-FZLBTGRLSA-N saframycin c Chemical compound O=C1C(C)=C(OC)C(=O)C2=C1[C@H](OC)[C@H]1CN3[C@@H](CNC(=O)C(C)=O)C(C(=O)C(OC)=C(C)C4=O)=C4C[C@H]3[C@@H]2N1C JIJFDUYXCLTCFT-FZLBTGRLSA-N 0.000 description 1
- JRGSNFZUTBSLSG-ZKNHNOBHSA-N saframycin d Chemical compound C1([C@@H]([C@@H]2C3)N4C)=C(O)C(OC)=C(C)C(O)=C1C(=O)[C@@H]4CN2[C@@H](CNC(=O)C(C)=O)C1=C3C(=O)C(C)=C(OC)C1=O JRGSNFZUTBSLSG-ZKNHNOBHSA-N 0.000 description 1
- WDQZQIAZHSHOFD-UHFFFAOYSA-N saframycin f Chemical compound CN1C(C2C#N)C(=O)C3=C(O)C(C)=C(OC)C(O)=C3C1C(C1)N2C(CNC(=O)C(C)=O)C2=C1C(=O)C(C)=C(OC)C2=O WDQZQIAZHSHOFD-UHFFFAOYSA-N 0.000 description 1
- PYOFDRKUKHPATO-JLUOOAMSSA-N saframycin h Chemical compound C([C@H](N1C)C2C#N)C(C(C(C)=C(OC)C3=O)=O)=C3[C@@H]1[C@H](C1)N2[C@@H](CNC(=O)C(C)(O)CC(C)=O)C2=C1C(=O)C(C)=C(OC)C2=O PYOFDRKUKHPATO-JLUOOAMSSA-N 0.000 description 1
- GATZXGIUISULHU-WDDJOWQOSA-N saframycin r Chemical compound C([C@@H](N1C)[C@@H]2C#N)C3=C(O)C(C)=C(OC)C(OC(=O)CO)=C3[C@H]1[C@H](C1)N2[C@@H](CNC(=O)C(C)=O)C2=C1C(=O)C(C)=C(OC)C2=O GATZXGIUISULHU-WDDJOWQOSA-N 0.000 description 1
- KLKJKXQSKPPFSJ-XFPFBUNZSA-N saframycin y3 Chemical compound C([C@@H](N1C)C2C#N)C(C(C(C)=C(OC)C3=O)=O)=C3[C@H]1[C@H](C1)N2[C@@H](CNC(=O)[C@H](C)N)C2=C1C(=O)C(C)=C(OC)C2=O KLKJKXQSKPPFSJ-XFPFBUNZSA-N 0.000 description 1
- DULAUWVTCHNVOZ-FSCDNRMKSA-N saframycin-yd2 Chemical compound C([C@@H](N1C)C2C#N)C(C(C(C)=C(OC)C3=O)=O)=C3[C@H]1[C@H](C1)N2[C@@H](CNC(=O)CN)C2=C1C(=O)C(C)=C(OC)C2=O DULAUWVTCHNVOZ-FSCDNRMKSA-N 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 125000003808 silyl group Chemical group [H][Si]([H])([H])[*] 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 150000003526 tetrahydroisoquinolines Chemical class 0.000 description 1
- 238000006257 total synthesis reaction Methods 0.000 description 1
- 238000005891 transamination reaction Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
C.
SYNTHETIC PROCESS FOR THE MANUFACTURE OF AN ECTEINASCHIDIN COMPOUND
The present invention relates to synthetic processes, and in particular it relates to synthetic processes for producing ecteinascidin compounds.
European Patent 309,477 relates to ecteinascidins 729, 743, 745, . 759A, 759B and 770. The ecteinascidin compounds are disclosed to have antibacterial and other useful properties. Ecteinascidin 743 is ; now undergoing clinical trials as an antitumour agent.
Ecteinascidin 743 has a complex tris(tetrahydroisoquinolinephenol) structure of the following formula (I):
OCH;
HO CH;
OCOCH;
H
CH, :
N——CH;
NV
0 i 0 OH (0) o=< J
CH30 . .
NH
HO
It is currently prepared by isolation from extracts of the marine tunicate Ecteinascidin turbinata. The yield is low, and alternative preparative processes have been sought.
A synthetic process for producing ecteinascidin compounds is described in US Patent 5,721,362, see also WO 9812198 which is incorporated herein by reference in full. The claimed method is long and complicated, there being 38 Examples each describing one or more steps in the synthetic sequence to arrive at ecteinascidin 743.
In the known synthetic process, a 1,4 bridge is formed using a 1- labile, 10-hydroxy, 18-protected hydroxy, di-6,8-en-5-one fused ring compound. As shown in Example 33, a compound (13) is converted to compound (14):
OMe o MOMO. 7) Me AllocHN one
Me oH hd 1) DMSO, Ti,0 ox po Me 1 ® r N-|-me 2 DIPEA AO) s 4d ZL BOR mel AT ove ® 9g Neu N \ Ps ) Duo Nm, \g en
ANON NH c “ T & ) 5) Acp0, CH,Cly . 13
According to the known synthetic process, a spiroquinoline is then formed in the 1,4 bridge by the steps of Examples 34 to 36, and the 18-MOM protecting group is removed to give ecteinascidin 770 which can then be converted to ecteinascidin 743.
Claim 25 of US 5,721,362 is directed at an intermediate phenol compound of a given formula (11), which we refer to also as
Intermediate 11 or Int-11. It has the following bis(tetrahydroisoquinolinephenol) structure (II):
OCH,
MOMO CH,
OH
H
CH; H
N——CH;
Nn lo) ; \-o CN
OTBDPS where MOM is a methoxymethyl substituent and TBDPS is a tert- butyldiphenylsilyl substituent.
From Intermediate 11 it is possible to synthesise another interesting antitumour agent, phthalascidin, see Proc. Natl. Acad. Sci.
USA, 96, 3496-3501, 1999. Phthalascidin is a bis(tetrahydroisoquinolinephenol) derivative of formula (III):
OCH, )
HO CH,
OCOCH;, }
CH, H r N——CH;,
NH
0] :
Lo EN
N
HH
In ecteinascidins 743 and 770, the 1,4 bridge has the structure of formula (IV): 4
Ho \ ai
CH;0
NH
HO
Other known ecteinascidins include compounds with a different bridged cyclic ring system, such as occurs in ecteinascidin 722 and 736, where the bridge has the structure of formula (V): { \ = J
HN NH ecteinascidins 583 and 597, where the bridge has the structure of formula (VI): & \ 4 0 ~ 7
H “NH, and ecteinascidin 594 and 596, where the bridge has the structure of formula (VII):
A
= J 0
The complete structure for these and related compounds is given in J. Am. Chem. Soc. (1996) 118, 9017-9023. This article is incorporated by reference.
Other literature on the ecteinasdin compounds includes: Corey,
E.J., J. Am. Chem. Soc., 1996, 118 pp. 9202-9203; Rinehart, et al.,
Journal of Natural Products, 1990, “Bioactive Compounds from Aquatic and Terrestrial Sources”, vol. 53, pp. 771-792; Rinehart et al., Pure and
Appl. Chem., 1990, “Biologically active natural products”, vol 62, Pp. 1277-1280; Rinehart, et al., J. Org. Chem., 1990, “Ecteinascidins 729, 743, 745, 759A, 759B, and 770: potent Antitumour Agents from the
Caribbean Tunicate Ecteinascidia turninata”, vol. 55, pp. 4512-4515;
Wright et al., J. Org. Chem., 1990, “Antitumour Tetrahydroisoquinoline
Alkaloids from the Colonial ascidian Ecteinascidia turbinata”, vol. 55, pp. 4508-43512; Sakai et al., Proc. Natl. Acad. Sci. USA 1992, “Additional anitumor ecteinascidins from a Caribbean tunicate: Crystal structures and activities in vivo”, vol. 89, 11456-11460; Science 1994, “Chemical
Prospectors Scour the Seas for Promising Drugs”, vol. 266, pp.1324:
Koenig, K.E., “Asymmetric Synthesis”, ed. Morrison, Academic Press,
Inc., Orlando, FL, vol. 5, 1985, p. 71; Barton, et al., J. Chem Soc. Perkin
Trans., 1, 1982, “Synthesis and Properties of a Series of Sterically .
Hindered Guanidine bases”, pp. 2085; Fukuyama et al., J. Am. Chem.
Soc., 1982, “Stereocontrolled Total Synthesis of (+)-Saframycin B”, vol. } 104, pp. 4957; Fukuyama et al., J. Am. Chem. Soc., 1990, “Total
Synthesis of (+) — Saframycin A”, vol. 112, p. 3712; Saito, et al., J. Org.
Chem., 1989, “Synthesis of Saframycins. Preparation of a Key tricyclic
Lactam Intermediate to Saframycin A”, vol. 54, 5391; Still, et al., J Org.
Chem., 1978, “Rapid Chromatographic Technique for Preparative
Separations with Moderate Resolution”, vol. 43, p. 2923; Kofron, W.G.;
Baclawski, L.M., J. Org. Chem., 1976, vol. 41, 1879; Guan et al., J.
Biomolec. Struc. & Dynam., vol. 10, pp. 793-817 (1993); Shamma et al., “Carbon-13 NMR Shift Assignments of Amines and Alkaloids”, p. 206 (1979); Lown et al., Biochemistry, 21, 419-428 (1982); Zmijewski et al.,
Chem. Biol. Interactions, 52, 361-375 (1985); Ito, CRC Crit. Rev. Anal.
Chem., 17, 65-143 (1986); Rinehart et al., “Topics in Pharmaceutical
Sciences 1989”, pp. 613-626, D. D. Breimer, D. J. A. Cromwelin, K. K.
Midha, Eds., Amsterdam Medical Press B. V., Noordwijk, The
Netherlands (1989); Rinehart et al., “Biological Mass Spectrometry”, 233-258 eds. Burlingame et al., Elsevier Amsterdam (1990); Guan et al.,
Jour. Biomolec. Struct. & Dynam., vol. 10 pp. 793-817 (1993); Nakagawa et al., J. Am. Chem. Soc., 111: 2721-2722 (1989);; Lichter et al., “Food and Drugs from the Sea Proceedings” (1972), Marine Technology
Society, Washington, D.C. 1973, 117-127; Sakai et al., J. Am. Chem.
Soc., 1996, 118, 9017; Garcia-Rocha et al., Brit. J. Cancer, 1996, 73: 875-883; and Pommier et al., Biochemistry, 1996, 35: 13303-13309.
Further compounds are known which lack a bridged cyclic ring system. They include the bis(tetrahydroisoquinolinequinone) antitumor-antimicrobial antibiotics safracins and saframycins, and the marine natural products renieramicins and xestomycin isolated from cultured microbes or sponges. They all have a common dimeric tetrahydroisoquinoline carbon framework. These compounds can be . classified into four types, types I to IV, with respect to the oxidation & ; pattern of the aromatic rings.
Type 1, dimeric isoquinolinequinones, is a system of formula (VIII) : most commonly occurring in this class of compounds, see the following table I.
Table [ :
Structure of Type I Saframycin Antibiotics.
OCH, o CH, o ' H
CH, Po 0]
N—CH,
Pa
CH;0 > 7” 5, Rub
H : H [e) R21
HN
PN
R258" ‘Rasp
Compound Rida Ri14b R21 R25a R2sb R25¢ saframycin A H H CN (0) (0) CHs saframycin B H H H 0 0] CHj3 saframycin C H OCHa3 H 0) 0 CH3 - saframycin G H OH CN 0) 0] CHj3 saframycin H H H CN OH CH2COCH CHa 3 saframycin S H H OH 0) Oo CH3 saframycin Y3 H H CN NH: H CH3 saframycin Yd; H H CN NH: H C2Hs saframycin Ad; H H CN 0) 0 C2Hs saframycin Yd2 H H CN NH2 H H saframycin Yao H Q?b CN NH2 H CHj3 saframycin Yab-q H Qb CN NH. H C2Hs . saframycin AH> H H CN Ha OHa CH3 saframycin AH2Ac H H CN H OAc CH3 : saframycin AH; H H CN OHa He CH3 saframycin AHi1Ac H H CN OAc H CHj saframycin AR3 H H H H OH CH3 @ assignments are interchangeable. b where the group Q is of formula (IX):
OCH, 0) CH,
O H
CH PB 0 : ” “N——CH,
NJ
: CHO H : 'H
Oo CN
HN }
NH— be
CHs
Type I aromatic rings are seen in saframycins A, B and C; G and
H; and 8 isolated from Streptomyces lavendulae as minor components.
~
A cyano derivative of saframycin A, called cyanoquinonamine, is known from Japanese Kokai JP-A2 59/225189 and 60/084288. Saframycins
Ya, Ydi, Adi, and Yd2 were produced by S. lavendulae by directed biosynthesis, with appropriate supplementation of the culture medium.
Saframycins Y2» and Y2b-a dimers formed by linking the nitrogen on the
C-25 of one unit to the C-14 of the other, have also been produced in supplemented culture media of S. lavendulae. Saframycins AR, (=AH3,), a microbial reduction product of saframycin A at C-25 produced by Rhodococcus amidophilus, is also prepared by nonstereoselective chemical reduction of saframycin A by sodium borohydride as a 1:1 mixture of epimers followed by chromatographic separation [the other isomer AH, is less polar]. The further reduction product saframycin ARs, 21-decyano-25-dihydro-saframycin A, (= 25- 8 dihydrosaframycin B) was produced by the same microbial conversion.
Another type of microbial conversion of saframycin A using a Nocardia o species produced saframycin B and further reduction by a
Mycobacterium species produced saframycin AH!Ac. The 25-O-acetates of saframycin AH2 and AH: have also been prepared chemically for . biological studies.
Type I compounds of formula (X) have also been isolated from marines sponges, see Table II.
Table II
Structures of Type I Compounds from Marine Sponges.
OCH, 0) CH; 0) H nA Re
CH;0 i" 7 Re 0 R21
Oo or
TTT suwbstmens ‘Risa Rw Ra RT renieramycin B OC2Hs H H -C(CH3)=CH-CH3; renieramycin C OH 0) 0) -C(CH3)=CH-CH3 renieramycin D OC2Hs Oo (0) -C(CH3)=CH-CH3 renieramycin E H H OH -C(CH3)=CH-CH3 renieramycin F OCH3 H OH -C(CH3)=CH-CHs3; xestomycin OCHs3; H H -CH3 _—_—mm
Renieramycins A-D were isolated from the antimicrobial extract of a sponge, a Reniera species collected in Mexico, along with the biogenetically related monomeric isoquinolines renierone and related compounds. The structure of renieramycin A was initially assigned ‘ with inverted stereochemistry at C-3, C-11, and C-13. However, careful examination of the !H NMR data for new, related compounds - renieramycins E and F, isolated from the same sponge collected in
Palau, revealed that the ring junction of renieramycins was identical to that of saframycins. This result led to the conclusion that the formerly assigned stereochemistry of renieramycins A to D must be the same as that of saframycins.
Xestomycin was found in a sponge, a Xestospongia species collected from Sri Lancan waters.
Type II compounds of formula (XI) with a reduced hydroquinone ring include saframycins D and F, isolated from S, lavendulae, and saframycins Mx-1 and Mx-2, isolated from Myxococcus xanthus. See table III.
Table III
Type II Compounds
OCH,
HO CH, lo) ” H
CHa : ~ OH
N——CH; a i eee = R14b
H : H : lo) R21
HN oP
R258" Yq25n : Substituents
Compound Rl4a R14b R21 R25a R25b R25¢ saframycin D 0] 0) 'H 0 Oo ~~ CHs saframycin F O 0) CN 0 ©) CHs saframycin Mx-1 H OCH3 OH H CHs NH: a saframycin Mx-2 H OCHs H H CHs NH2 ? "The type III skeleton is found in the antibiotics safracins A and B, ~ isolated from cultured Pseudomonas fluorescens. These antibiotics of formula (XII) consist of a tetrahydroisoquinoline-quinone subunit and a tetrahydroisoquninolinephenol subunit. :
OCH;
HO CH; 0 H
H=
CH, HP
Y N——CHa,
CHsO Ng 3 na BH J o R21 i;
HN
PL
: NH, where R2! is -H in safracin A and is -OH in safracin B.
Saframycin R, the only compound classified as the Type IV skeleton, was also isolated from S. lavendulae. This compound of
SUBSTITUTE SHEET (RULE 26)
formula (XIII), consisting of a hydroquinone ring with a glycolic ester sidechain on one of the phenolic oxygens, is conceivably a pro-drug of saframycin A because of its moderate toxicity. 0 OCH, o) CH,
HO
CH, 5% 0
N—CH;
CH;0 ~ DH : OH CN
HN
CH
AY 3 oO
All these known compounds have a fused system of five rings (A) . to (E} as shown in the following structure of formula (XIV): 17 } 18 16 4 11 > O 15 5 10 3 XN D 20
B Cc 1a 7 (4) N 13 8 i 2
The rings A and E are phenolic in the ecteinascidins and some other compounds, while in other compounds, notably the saframycins, the rings A and E are quinolic. In the known compounds, the rings B and D are tetrahydro, while ring Cis perhydro.
The need remains for alternative synthetic routes to the ecteinascidin compounds and related compounds. Such synthetic routes may provide more economic paths to the known antitumour agents, as well as permitting preparation of new active compounds.
This invention relates to synthetic processes for the formation of intermediates, derivatives and related structures of ecteinascidin or other tetrahydroisoquinolinephenol compounds.
In one aspect, the present invention provides a process for preparing an ecteinascidin product with a spiroamine-1,4-bridge. The process involving forming a 1,4 bridge using a 1-labile, 10-hydroxy, 18- protected hydroxy, di-6,8-en-5-one fused ring compound, where the ¥ fused ring is the formula (XIV). In the present invention, the C-18 ) protection is removed before spiroamine introduction.
Suitable starting materials for the new synthetic processes include compounds related to the natural bis(tetrahydroisoquinoline) alkaloids. Such starting materials may be prepared either from the different classes of saframycin and safracin antibiotics available from different culture broths as detailed in WO 0069862 or by other synthetic or biochemical processes. In this respect, WO 0069862 is incorporated herein in full by reference. The present PCT application claims priority from application PCT/GB 00/01852 which was published as WO 0069862. We incorporate that text by reference to the extent that there is disclosure therein which is not in the present specification.
In one particular aspect, the present invention is directed at the use of the compound Intermediate 21 in a number of new synthetic processes for the preparation of ecteinascidin 743 and related compounds, xn OMe
HO Me
Me @® N=|-Me
N
=
[0] NH 21 }
The Intermediate 21 has a 5-allyloxy group, where the allyl group serves to protect the 5-hydroxy group. It will be understood that other protecting groups can easily be employed, and that the present invention extends generally to the use of other such S-protected hydroxy compounds.
FORMATION OF ECTEINASCIDIN 743 AND RELATED COMPOUNDS
In general, the conversion of Intermediate 21, or a related compound, to an ecteinascidin product involves the following key transformations: (a) Conversion of the NH2 to OH by reaction, for example with sodium nitrite in acetic acid. (b) E-ring phenol protection. (c) Esterification by protecting the primary 1-hydroxy function with a protected cysteine sidechain. (d) Deprotection of allyl group and oxidation.
(e) Creation of the bridged ring by cyclization reaction. (f) Deprotections of E-ring phenol and the cysteine moiety (8) Quinoline Introduction by Trans-amination and Petter Spengler reactions.
The high functionality of the intermediate compounds necessitates the use of protecting groups for the E-ring phenol and for the cysteine sidechain in order to prevent unwanted side reactions.
As such, a number of alternative intermediates can be generated : dependent on the particular selection of protecting groups. . Different possible sequences are possible for combining these transformations dependent primarily on the protecting groups selected for the phenol ring and for the amine of the cysteine sidechain.
The total number of synthetic transformations is also a function of the protecting groups selected.
By way of illustration, the use of different combinations of protecting groups is described below for six typical routes for the preparation of
ET-743 from Intermediate 21, also referred to herein as SF21.
Route Phenol Protection Cysteine Protection Number of steps 1 MOM Boc 12 2 MEM Boc 10
3 MEM Cbz 11 4 MOM Alloc 13
S MEM Alloc 13 6 MOM Cbz 15
As the skilled artisan will readily appreciate, the reaction schemes described herein may be modified and/or combined in various ways, and the alternative sequences of steps and the compounds generated therefrom are part of this invention.
Additionally, the use of other protecting group strategies not : detailed is also part of this invention.
PROCESS DETAILS OF Six TYPICAL SYNTHETIC ROUTES
Full reaction schemes for each route are in the following Schemes 1 to 6.
Scheme 1 - ET-743: Hemisynthetic Alternative Route 1 o 2 2 2 ) 2 3 = 1 ~ as; THA : i 9 iQ 2d a %o EVP $
Fa o Q ~~ 2 bi = [1 0 2 3 74 2 [= = 5 . Q, & 5 ul $ £82 £ . al z 955 |%% 3 #3 258 Id a : TESA § @ + 2 o [eo] ES) ° E £ o
W, Z2 —a/ 2A EN 4-4 AN : CI \ A & os I Og 2 = ° =-0 = Zz ! a oO © [»] 3 © Ws: 2 a 8 3 < I Bi
O qn - o [o] = ~~ ( bi 2d = > = Tr 8 74 3 [eo] 5 o £ z g o_o 8 . tls d oP 1 : 3 = do |£ : o I 2 [7] : gg ° = 3 oN [] . SWS £10 o | SN: lo] ° /—° BE PY } =-0 Zz 3 ~ 2 . C1) d Z “ZF o = >, 5 3 = "8 2 oy —o / 3 ° 2d’ Z 3 02 v © 3 ? . [eo] $ o’ = [+] [ x oN } 3 ad 3 2 @ 2 © L ou z © 2 VAR o |Z x ° 3 [4] o +=2.5 0% ine g 1 5 © 28 ¢ ig d|£ <) S a&
Fe 3% 2 = © o 2 2 = ats SYENIDT i We 74 o =z @ Z > $ © ils = Ss Q GQ o 2-0 Z © q ha jutl z 3
I] 2.5 . Ll a o yo peas Es
Cot ares d © g 8 - = zZ WN o [4] 2 -
Yd (2 Bi g | JS 3 2 © 8 %%
I
SUBSTITUTE SHEET (RULE 26)
Scheme 2 ~ ET-743: Hemisynthetic Alternative Route 2 © [+]
PS
Zz . 9 ¢ () : so N ONL : z$ a 2 Ea 0
So RT al
I [1] [o} g 2] Zz = g MAY 8 5g hat >. 9 2 z 4 2 [} =
Zz 32 2 518 2 $ $ = ot 1 Le
Sim 1 & = la = wu 4 o o ns
Ys 8 i, a ° ©, Zz hy 0 ry 2 -} Vo § = = = é 9 0 zz [+] §) 7 wg < J 2 Q *
AN =z 2 5 g © 5
I] i] z =
T Zz © So re) 9 [+] oN 5 = = a Zz = 2) ' a ° 553 z= pe . 2 2 - ib a® sii] 2 5) = cael § @ ZL [o] Ll] g 3 I: 1%, Qu =a 5| »8 2 2 og © 2 | oot ODT Pa 2 [o] z= z oc [o] [o} = : = : oJ 8B v2 ° = g Z O S -— £ = T
HY : :
Zz z oO CY To] — fo] 941), =
I = °c @ o” 3 $ = 28a 21 ed @ S 93 2, 4 oO [Ve = = = . g|° Se °\ ¢% ¢ = [y [eo] ne [TH =z [} - £2 z /S\F (S ON é|3 ve C8 = 2 < g " z [3 re Ng © iu Zz © 3 oz ?
H p = Ye) dg 5 2 = ° “Jt 5 ) 8 § X 2% {or 5 - on o =e “ ™ x | 5d Y=-2 or 0 {Y o &| 2 SS 3d od 5 ole ae 4 [+) @ 5 - ~~ £ c - Ne
SUBSTITUTE SHEET (RULE 26)
Scheme 3 — ET-743: Hemisynthetic Alternative Route 3 [ov] o 5
IN ui © ]
Z 4 [o] oui 2 oe Za 2 33 3 8 °% =X J p-4 IT [] O g [o] “iQ => = = © ri Z 0 b 3 £ = (o) - > S : a SRE “\ z [o} [23 i of [o] ol 7 3 E % z Za )2 ; 2 2 © o
AE : CE )=C3 518 2 2 8 o g © gs © J 2 gs z3\ N = [=] 5 § Ts z z se 2 Fal 5 i 2 @ No ES o 2 . 1] = | Oo 3 [=] Oo Oo = . [eo] | wv N [4 J I [4 172]
Az (2 3 HA = 9 “ng 4 - [-]
Z © & oo 2 a 0 2 2 = 2 2 Zz it 87 5 © ] a gs % a Ssi gfs| 3 § g -& an < / gg © S85] & & LN 8 - OA o 1%, Qo R542 a J = ® 2 [=} 2 2 = ES = o
B| ot © \ J ! » 8 2 ul Q FN =z 2 5
E 0 ni; Z © he 2 H z - ® o n Ww 2 oS: Z 5 ) 5 2-2 ES +] i Cl = a9
Q
=z 2 ° (CD ° ~ o> °] “oid J - Nm
Zz 5 dg © © = o hot = a o 2 = as HE: HR g © £15 05 ® 9 8 g 2 © =z £0 3 £3 2 =F FN 3 HAN. C8 ° ENF t g Q wl z ] oO . iE 2 0 = 2 d= 2 = °o 8
EO z ”
Ww, x = > >, o z 2 "Oe o 0 3) 4 z Zz = T Q 3 g1= hes i|2 : 7 J Fl o 4 2 Oo g o.
SUBSTITUTE SHEET (RULE 26)
Scheme 4- ET-743: Hemisynthetic Alternative Route 4 2 g @ — = 55 [o] \ y, i N $ $ JE « "NE. Sz g z i, 2" 8 22
E $ ° x é = 8 do Neo 2) 2 [ 0” 2 © 3 ? © 7 = © 0 z z - = g "QO °o § 2 $3 ENS 3 A = 87 5 \ © i 2 Zz 2 thy 5 Tz = o 2 (*] © \ 0% zg FS ca $2 & < © o- d og: EE EE © 9g = . 3 Z © =z 5
Rcd Jk ~ - ota, 0 jh 74 0 [+] 2 2 Ho br 2
ES 5 §) \ " ; “N\ =z x 8 2 g Fr) g [od NO Zz © 2 21/538 3 LN =o 3 : o = z © 9 J 2 - = “og . £ os: " o< 9 { aE "
Z 85 2 © °=y—o fo] a fo x Z 1) g o 4 bi 8 5 £ °
P & id FH o =
PB ° TI/ Ne EJ 7 { o : ] 5-{ = 28 ; © 2 —- a
Eig 4 0% Te FF ol = - ° o gg g Xa Wai © g e 2 - Zz = = 5 e 0 rE) o 2 IT z CO) 7 o {) o —On/ 4 8 2 z 2 0 yo el p "Oz 2 J 3 9
EK] oO a o ed a 3 I|3 74 ° [=) 2 o 3, z w g © A) I = 2 2 0
Fl3 0 8 2 7
Q > = Z Bb o 23 ] Zz 2 £ = a 2 0 i o 2 2 I © (o] TO « as Pa yo ° 2 Be 5 = . Zz 02 bi 2s £ °
Q ™ ea @, bi £ 5 81s / 4 Yo FR
SUBSTITUTE SHEET (RULE 26)
Scheme 5- ET-743: Hemisynthetic Alternative Route 5 o £ 3 2 3 = Z © © i &) = i z 52 5 1 S 2 g = A\ z 2 |Z 3] Zz Oo § irs] = < 2 = 5 0 Z - 2 5
T - Ny ®
Yo ir Wek:
Pe o 0% (e] 1 s J z
N g oO Q “0g
T|o I 2 ~ 8% ° § 5 2a = © a £ oN 3 Z 2 lo] w = 5 o 2 © 9 o 2 2g a 2R3 Zz o °g J 5 I =L4 5 a & o [=] 1 29 EE = go o =
F\P8 cam| § @ 2 8 }
Q - . T fr] Z 0 © o 2 £ 2 <) ii po 0) © 2 CI) g
Vd % 2 = 0 0 4 do 0 2 = CHEE = © WV, ! P ° — = ~ 2 . 81x Io! 5 z - 2 2 ils & Zz 0 =o ° : = = T OQ 2 = 2 © fol iG 0 2 2 o (CY 0 { xz z = : Bi Sa 8 : © CH 22 = oO yo g X OB A) cg o
ES Zz 5 2 CI p, J 2 5 £ - [7] . ° &, o 5 » 2 Me S
V4 do a &: 5 3x2 2 3 = © 3 =o oO of k @ X 2 g Q = 8 & 28 Sh Cd : ja] ° ® . mE AN =z = = - - [o) ~Qp [+] i o z Z [o] a 4 > © = $e = T - 2) “i = ' fo] : * Zz © Ws o CY (o} oF * 0
A =z J 2 yO ” g "By go = Iq ° 2° = °& J $ E o @ [=] 4 Fld g ad 1 ; 7 J = | £ 2 2 [o) 2 I. 4, pe ’
Q = r-) © = i a (<] o ° o - = [a] om [] = 28 g % 5 5 < 2 4 2 > 2 oO - [eo] wg) 2 £ ° (LY 0 Zo) . © 5: > od o =o 3 = ii] o Oe 8 z Q o
T Zz = bf o < < J
HN Q [o]
Waly: £5 s| 8 2s zg
SUBSTITUTE SHEET (RULE 26)
Scheme 6 — ET-743 Hemisynthetic Alternative Route 6 2 a @ = 2 2 2 ] o| = [1 e =
Zz = 219 3 3 "oO o 13 8 Eo 3 R o 3 2 -y = =
Dre © i °o ‘ 2 © < J [eo] wd 4 2 © z To z =
Ne F iw 2 2 & a
Pa I o x = © °< 3 , a i o ES % © [o] iii 33 gg f°
Ne & I) - z i wv, F 2 CT) 512% 2 $ @ = [«] Q ) i » & O = 2 4 2 I oN z ] fof ne) z BK 1 2 z 0 z . -—- to) g io o — 0 a 2 ° CY Q oo
Q - o 2 (o] . = < o J o g 2 fo) e 5-{ =| 2
J = Fe) a of 2 u = ae © 2 2 a 2%
Zz z 4 J o Gp 2 = 3 =z =] e "iQ
Zz 5 ® — Z a o - aS o o
C3 Dra o [+] . © < J = ] [o x = 21¢ =| 2 : = 2
Wan th Ne $ See Ht: [3
[1] = 2 = 4 1 ” 8 x 8 =
A\ =z I 8 a 3 © g "wo Z z F ]
Zz ©0 o g - ° 3 Te ° < on = (Y bi = g © 5 2/2 [ond
SUBSTITUTE SHEET (RULE 26)
In route 1, protection of the E-ring phenol is achieved in three steps involving protection /deprotection of the amine of SF21 with Troc.
For routes 1 and 2, protection of the cysteine sidechain with Boc allows the phenol and cysteine groups to be deprotected in a single step rather than as two separate steps. For the rest of the routes, an additional deprotection step is required.
For route 2, Intermediate 25 is avoided through the use of the direct esterification methodology and the subsequent protection of the phenol with the MEM group.
In routes 2 and 3 protection of the E-ring phenol is delayed until after the diazotisation and esterification steps thereby allowing the phenol to be protected in a single step rather than by the three step : sequence of route 1. :
For routes 1, 2 and 3, direct esterification of the primary alcohol with the cysteine derivative eliminates the unproductive protection/deprotection steps of the primary alcohol with a silyl group (routes 4 and 5) thereby shortening the sequence by two steps.
Route 6 only contemplates herein the last steps from intermediate 161, which can be easily obtained from intermediate 21.
In routes 4 and 5 the primary alcohol produced by the initial diazotisation step is protected with silicon to allow selective protection of the E-ring phenol and avoiding intermediate 25. Following
Claims (29)
1. A process for preparing an ecteinascidin product with a spiroamine-1,4-bridge, the process involving forming a 1,4 bridge using a 1-labile, 10-hydroxy, 18-protected hydroxy, di-6,8-en-5-one fused ring compound, wherein C-18 protection is removed before spiroamine introduction.
2. A process according to claim 1, wherein the ecteinascidin product has a 21-hydroxy group, the process including converting a 21-cyano group to the 21-hydroxy group.
; 3. A process according to claim 1 or 2, wherein the spiroamine is a spiroquinoline.
4. A process according to any preceding claim, wherein the 18- protected group of the 1-labile, 10-hydroxy, 18-protected hydroxy, di- 6,8-en-5-one fused ring compound is protected with: MOM, methoxymethyl; or MEM, methoxyethoxymethyl group.
5S. A process according to any preceding claim, wherein the 1-labile group is an N-protected cysteinyloxymethylene group of the formula -CH2-O-CO-CNHProt!-CH>-S-H.
6. A process according to claim 5, where Prot! is: Bog, t- butyloxycarbonyl; Troc, 2,2,2-trichloroethyloxycarbonyl; Cbz, benzyloxycarbonyl; or Alloc, allyloxycarbonyl.
7. A process according to claim 5 or 6, wherein Prot! is removed in the same step as C-18 protection.
8. A process according to claim 5, 6 or 7, wherein the 1-labile group is generated from a 1-substituent of the formula: -CH2-O-CO-CNHProt1-CH,-S-Prot2.
9. A process according to claim 8, wherein Prot? is Fm, O- fluorenylmethyl. ’
10. A process according to claim 8 or 9, wherein the 1-substituent of the formula: -CH2-O-CO-CNHProt!-CH»-S-Prot2. is formed by esterification of a -CH2-O-H substituent.
11. A process according to claim 10, wherein the esterification is carried out before formation of the 10-hydroxy, di-6,8-en-5-one structure.
12. A process according to claim 10, wherein the esterification is carried out after introduction of the 10-hydroxy, di-6,8-en-5-one structure.
13. A process according to any preceding claim, which starts from a l-aminomethylene, 5-protected hydroxy, 7,8-dioxymethylene, 18- hydroxy, 21-cyano fused ring compound
14. A process according to claim 13, where the l-aminomethylene group is temporarily protected to allow protection at the 18-hydroxy group, and the temporary protection is removed.
15. A process according to claim 13, wherein the C-18 hydroxy group . is protected after formation of a 1-ester function.
16. A process according to claim 13, wherein the l-aminomethylene group is converted to a 1-hydroxymethylene group and the 1- hydroxymethylne group is temporarily protected, to allow protection at the 18-hydroxy group, and the temporary protection is removed.
17. A process according to claim 1, wherein the 1-labile, 10-hydroxy, 18-protected hydroxy, di-6,8-en-5-one fused ring compound is prepared by steps starting from a 21-Nuc compound with a structure of formula (XIV): 17 18 16 4 11 0 15 6 10 3 5 D 20 B C 14 7 (4) N 13 8 ] 71 where at least one ring A or E is quinolic, and where Nuc Indicates the residue of a nucleophilic agent.
18. A process according to claim 17, wherein the compound of formula (XIV) is cyanosafracin B.
19. A process according to any preceding claim, wherein the product is of formula (XXIIb): R'® CH, R® RR HC gy R' El SF : N R12 R42 14b (o) i R . AN Rr! g21 where: Rl and R* together form a group of formula (IV), (V), (VI) or (VII): . . 4 1 4 4 / ( . 0] 1 1 0 S$ ®) 7 ( ( CH,0 Co! HNN o % o\ H 7 HO , , Ne or © ; RS is -OH or a protected or derivatised version of such a group; R142 and R14" are both -H or one is -H and the other is -OH or a protected or derivatised version of such a group, -OCH3 or -OCH,CHs, or R142 and R14b together form a keto group; R12 js -NCHza-; RIS is -OH or a protected or derivatised version of such a group; and R!8 is -OH or a protected or derivatised version of such a group.
20. A process according to claim 19, wherein R5 is alkanoyloxy of 1 to S carbon atoms.
21. A process according to claim 20, wherein RS is acetyloxy.
22. A process according to claim 19, 20 or 21, wherein R42 and R14b are hydrogen. -
23. A process according to any of claims 19 to 22, wherein R!5 is hydrogen.
24. A process according to any of claims 19 to 23, wherein R2! is -OH or -CN.
25. A process according to claim 1 1, wherein R7 and R® together form a group -O-CH2-O-.
26. A process according to any of claims 19 to 25, wherein R! and R* together form a group of formula (IV):
( 0) oJ CH;0 2 . NH HO
27. A process according to any preceding claim, wherein the ecteinascidin product is ecteinascidin 743.
28. A process step in the manufacture of an ecteinascidin comopund, the step comprising removing both protecting groups in a single step, in accordance with the following scheme: . NHProthH NH Proto OMe 2 OMe O \ Me O=¢" "| HO Me AcO 5 S AcO S me N—J-Me Me YT N-]-Me N 0] i (0) N z 0 CN 0 EN where ProtNH is amino protecting group, and ProtOH is a hydroxy protecting group.
29. A process according to any of claims 1 to 27, which includes the process step according to claim 28.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0010852 | 2000-05-15 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200208186B true ZA200208186B (en) | 2003-07-18 |
Family
ID=30129756
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200208186A ZA200208186B (en) | 2000-05-15 | 2002-10-10 | Synthetic process for the manufacture of an ecteinaschidin compound. |
Country Status (1)
Country | Link |
---|---|
ZA (1) | ZA200208186B (en) |
-
2002
- 2002-10-10 ZA ZA200208186A patent/ZA200208186B/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5478932A (en) | Ecteinascidins | |
CN100475822C (en) | Synthesis method for producing ecteinascidin compound | |
CA2406080C (en) | Antitumoral ecteinascidin derivatives | |
ES2292237T3 (en) | SEMISINTETIC ECTEINASCIDINS. | |
AU2008207381B2 (en) | New antitumoral derivatives of ET-743 | |
US7919493B2 (en) | Anititumoral ecteinascidin derivatives | |
ZA200208186B (en) | Synthetic process for the manufacture of an ecteinaschidin compound. | |
DE60112286T2 (en) | SYNTHETIC PROCESS FOR THE PREPARATION OF ECTEINASCIDINE DERIVATIVES | |
AU2001256496A1 (en) | Synthetic process for the manufacture of an ecteinascidin compound | |
ZA200207850B (en) | Antitumoral ecteinascidin derivatives. | |
NZ521808A (en) | Synthetic process for the manufacture of an ecteinaschidin compound |